Literature DB >> 8058642

Bioequivalence: performance of several measures of extent of absorption.

F Y Bois1, T N Tozer, W W Hauck, M L Chen, R Patnaik, R L Williams.   

Abstract

The determination of the area under the concentration-time curve (AUC) is the method most commonly used by regulatory agencies to assess extent of drug absorption after single-dose administration of oral products. Using simulations, several approaches toward measuring the actual area, in whole or part, were tested. In addition, the performance of the peak concentration (Cmax), usually taken as a measure of the rate of absorption was assessed evaluating extent. Model scenarios for drugs with typical mean characteristics and statistical distributions were investigated. Using different kinetic models of disposition, the time course of the drug concentration in plasma was simulated. Intraindividual and interindividual variability and assay error were modeled using Monte Carlo techniques. The accuracy, precision, and ease of use of the various measures of extent were evaluated, and statistical power analyses were performed. Among the measures tested, the most reliable were the AUC computed up to the time of the last quantifiable concentration, without extrapolation, and Cmax. However, being also sensitive to rate, Cmax as a measure of extent is of limited potential.

Mesh:

Year:  1994        PMID: 8058642     DOI: 10.1023/a:1018932430733

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  1 in total

1.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12
  1 in total
  17 in total

1.  Evaluation of truncated areas in the assessment of bioequivalence of immediate release formulations of drugs with long half-lives and of Cmax with different dissolution rates.

Authors:  P Sathe; J Venitz; L Lesko
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

2.  Novel direct curve comparison metrics for bioequivalence.

Authors:  J E Polli; A M McLean
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

Review 3.  Measures of exposure versus measures of rate and extent of absorption.

Authors:  M L Chen; L Lesko; R L Williams
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Use of truncated areas to measure extent of drug absorption in bioequivalence studies: effects of drug absorption rate and elimination rate variability on this metric.

Authors:  J Kharidia; A J Jackson; L A Ouderkirk
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

5.  Truncated area under the curve as a measure of relative extent of bioavailability: evaluation using experimental data and Monte Carlo simulations.

Authors:  J Gaudreault; D Potvin; J Lavigne; R L Lalonde
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

6.  Evaluation of pharmacokinetic studies: is it useful to take into account concentrations below the limit of quantification?

Authors:  H Humbert; M D Cabiac; J Barradas; C Gerbeau
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

7.  Evaluation of bioequivalence of highly variable drugs using clinical trial simulations. II: Comparison of single and multiple-dose trials using AUC and Cmax.

Authors:  A A el-Tahtawy; T N Tozer; F Harrison; L Lesko; R Williams
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

8.  Absorption rate vs. exposure: which is more useful for bioequivalence testing?

Authors:  T N Tozer; F Y Bois; W W Hauck; M L Chen; R L Williams
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

9.  The duration of measuring partial AUCs for the assessment of bioequivalence.

Authors:  L Endrenyi; F Csizmadia; L Tothfalusi; A H Balch; M L Chen
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

10.  Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations.

Authors:  Vangelis Karalis; Panos Macheras; Meir Bialer
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.